IART — Integra LifeSciences Holdings Balance Sheet
0.000.00%
- $915.23m
- $2.48bn
- $1.61bn
- 59
- 74
- 35
- 58
Annual balance sheet for Integra LifeSciences Holdings, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 470 | 513 | 457 | 309 | 274 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 233 | 243 | 274 | 259 | 272 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 1,237 | 1,154 | 1,161 | 1,058 | 1,082 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 371 | 396 | 460 | 496 | 550 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Other Long Term Assets | |||||
| Total Assets | 3,615 | 3,782 | 3,890 | 3,782 | 4,037 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 401 | 340 | 321 | 307 | 922 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 2,100 | 2,098 | 2,085 | 2,194 | 2,492 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Other Equity | |||||
| Total Equity | 1,515 | 1,685 | 1,804 | 1,588 | 1,545 |
| Total Liabilities & Shareholders' Equity | 3,615 | 3,782 | 3,890 | 3,782 | 4,037 |
| Total Common Shares Outstanding |